Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Phase I, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours or Lymphoma

Trial Profile

A Two-part, Phase I, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours or Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NUC 7738 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms NuTide: 701
  • Sponsors NuCana
  • Most Recent Events

    • 13 Nov 2019 According to a NuCana media release, data from this study is expected in 2020.
    • 29 Oct 2019 According to a NuCana media release, six patients have received NUC-7738 to date in this trial.
    • 17 Jul 2019 According to a NuCana media release, first patient has been dosed in the trial. Oxford Early Phase Trials unit has enrolled the global first cancer patient to receive NUC-7738.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top